Stryker Co. (NYSE:SYK) – Stock analysts at Northcoast Research raised their Q1 2019 EPS estimates for shares of Stryker in a research note issued to investors on Monday, April 16th. Northcoast Research analyst D. Keiser now anticipates that the medical technology company will earn $1.77 per share for the quarter, up from their prior estimate of $1.76.
Other research analysts also recently issued reports about the company. Royal Bank of Canada reiterated a “buy” rating and set a $175.00 price objective on shares of Stryker in a research note on Tuesday, January 9th. SunTrust Banks reiterated a “buy” rating and set a $179.00 price objective (up from $161.00) on shares of Stryker in a research note on Friday, January 26th. Guggenheim reiterated a “buy” rating on shares of Stryker in a research note on Wednesday, January 31st. Piper Jaffray reiterated a “buy” rating and set a $170.00 price objective on shares of Stryker in a research note on Wednesday, January 31st. Finally, ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and sixteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $165.27.
Shares of NYSE:SYK opened at $163.55 on Wednesday. The company has a market cap of $61,310.16, a P/E ratio of 25.20, a P/E/G ratio of 2.35 and a beta of 0.70. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. Stryker has a 12-month low of $131.20 and a 12-month high of $170.00.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year.
Institutional investors and hedge funds have recently modified their holdings of the company. Truewealth LLC purchased a new stake in shares of Stryker during the 4th quarter worth approximately $110,000. Sawyer & Company Inc purchased a new stake in shares of Stryker during the 4th quarter worth approximately $125,000. Sit Investment Associates Inc. raised its holdings in shares of Stryker by 114.3% during the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 440 shares in the last quarter. Virtue Capital Management LLC purchased a new stake in shares of Stryker during the 4th quarter worth approximately $133,000. Finally, Oak Point Wealth Management purchased a new stake in shares of Stryker during the 4th quarter worth approximately $145,000. 75.66% of the stock is currently owned by institutional investors and hedge funds.
In other news, Chairman Kevin Lobo sold 39,808 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $162.90, for a total transaction of $6,484,723.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of the company’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $160.00, for a total value of $120,000.00. Following the sale, the chief financial officer now directly owns 3,535 shares in the company, valued at $565,600. The disclosure for this sale can be found here. Insiders sold a total of 143,239 shares of company stock valued at $23,608,485 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 annualized dividend and a yield of 1.15%. Stryker’s payout ratio is 28.97%.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/20/q1-2019-eps-estimates-for-stryker-co-syk-raised-by-analyst.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.